MBCART-191 is under clinical development by Miltenyi Biomedicine and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MBCART-191’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MBCART-191 is under development for the treatment of relapsed and refractory acute lymphocytic leukemia, B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. It is administered through the intravenous route. The therapeutic candidate consists of T cells engineered to express chimeric antigen receptors (CAR T-cells). It acts by targeting cells expressing CD19 antigen and being developed based on Mono CART technology. It was also under development for the treatment of acute lymphoblastic lymphoma.
Miltenyi Biomedicine overview
Miltenyi Biomedicine, a subsidiary of Miltenyi Biotec GmbH, is a biopharmaceutical company that develops innovative cell and gene therapies and regenerative therapies for cancer treatments.
For a complete picture of MBCART-191’s drug-specific PTSR and LoA scores, buy the report here.